Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:26787558  

SPECC1L deficiency results in increased adherens junction stability and reduced cranial neural crest cell delamination.

Nathan R Wilson | Adam J Olm-Shipman | Diana S Acevedo | Kanagaraj Palaniyandi | Everett G Hall | Edina Kosa | Kelly M Stumpff | Guerin J Smith | Lenore Pitstick | Eric C Liao | Bryan C Bjork | Andras Czirok | Irfan Saadi
Scientific reports | 2016

Cranial neural crest cells (CNCCs) delaminate from embryonic neural folds and migrate to pharyngeal arches, which give rise to most mid-facial structures. CNCC dysfunction plays a prominent role in the etiology of orofacial clefts, a frequent birth malformation. Heterozygous mutations in SPECC1L have been identified in patients with atypical and syndromic clefts. Here, we report that in SPECC1L-knockdown cultured cells, staining of canonical adherens junction (AJ) components, β-catenin and E-cadherin, was increased, and electron micrographs revealed an apico-basal diffusion of AJs. To understand the role of SPECC1L in craniofacial morphogenesis, we generated a mouse model of Specc1l deficiency. Homozygous mutants were embryonic lethal and showed impaired neural tube closure and CNCC delamination. Staining of AJ proteins was increased in the mutant neural folds. This AJ defect is consistent with impaired CNCC delamination, which requires AJ dissolution. Further, PI3K-AKT signaling was reduced and apoptosis was increased in Specc1l mutants. In vitro, moderate inhibition of PI3K-AKT signaling in wildtype cells was sufficient to cause AJ alterations. Importantly, AJ changes induced by SPECC1L-knockdown were rescued by activating the PI3K-AKT pathway. Together, these data indicate SPECC1L as a novel modulator of PI3K-AKT signaling and AJ biology, required for neural tube closure and CNCC delamination.

Pubmed ID: 26787558

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NCRR NIH HHS, United States
    Id: S10 RR027564
  • Agency: NIGMS NIH HHS, United States
    Id: P20 GM104936
  • Agency: NIGMS NIH HHS, United States
    Id: P20 GM103418
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM102801
  • Agency: NICHD NIH HHS, United States
    Id: P30 HD 002528
  • Agency: NCRR NIH HHS, United States
    Id: S10RR027564
  • Agency: NICHD NIH HHS, United States
    Id: P30 HD002528

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Novus Biologicals (tool)

RRID:SCR_004286

Commercial antibody vendor which supplies antibodies and other products to life science researchers.

View all literature mentions

Cytoskeleton (tool)

RRID:SCR_013532

An Antibody supplier

View all literature mentions

U2OS (tool)

RRID:CVCL_0042

Cell line U2OS is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

C57BL/6J (tool)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions